{"title":"Agomelatine: a new treatment for depression","authors":"Professor Bill Deakin","doi":"10.1002/fps.48","DOIUrl":null,"url":null,"abstract":"<p>It is estimated that depression carries the greatest burden of disability in established economies. A range of treatments are available, and selective serotonin reuptake inhibitors (SSRIs) are currently the most commonly prescribed class of antidepressant. In this article, the author discusses agomelatine, a novel antidepressant recently licensed by the European Medicines Agency (EMEA), the evidence for its use, and its potential place in therapy. Copyright © 2009 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 2","pages":"14-19"},"PeriodicalIF":0.0000,"publicationDate":"2009-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.48","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.48","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
It is estimated that depression carries the greatest burden of disability in established economies. A range of treatments are available, and selective serotonin reuptake inhibitors (SSRIs) are currently the most commonly prescribed class of antidepressant. In this article, the author discusses agomelatine, a novel antidepressant recently licensed by the European Medicines Agency (EMEA), the evidence for its use, and its potential place in therapy. Copyright © 2009 John Wiley & Sons, Ltd.
阿戈美拉汀:一种治疗抑郁症的新方法
据估计,在成熟经济体中,抑郁症是造成残疾的最大负担。治疗方法有很多,选择性血清素再摄取抑制剂(SSRIs)是目前最常用的抗抑郁药。在这篇文章中,作者讨论了阿戈美拉汀,一种最近获得欧洲药品管理局(EMEA)许可的新型抗抑郁药,它的使用证据,以及它在治疗中的潜在地位。版权所有©2009 John Wiley &儿子,有限公司
本文章由计算机程序翻译,如有差异,请以英文原文为准。